Clinical trials: Relapsed/Refractory Solid Tumors
Childhood Cancer, Childhood Solid Tumor
Precision Medicine for Every Child With Cancer
To improve outcomes for childhood cancer patients through the implementation of precision medicine.
- Conditions
- Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor, Childhood Leukemia
- Trial name
- ZERO2 (NCT05504772)
- Testing
- Whole Genome Sequencing, RNA seq, DNA Methylation
- Where
- 11 sites in Australia, New Zealand
- Volunteers
- 3,500 people
- Sponsor
- Australian & New Zealand Children's Haematology/Oncology Group
Unresectable Advanced Solid Tumors, Biliary Tract Tumors, Gastric Cancer, Small Cell Lung Cancer
Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors
An exploratory clinical study of short course radiotherapy combined with surufatinib and sintilimab in the treatment of relapsed and refractory advanced solid tumors
- Trial name
- NCT05527821
- Testing
- Surufatinib, Sintilimab, Short course radiotherapy
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer
Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
A phase I/II study of PI3Kinase inhibition (copanlisib) and anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions in mismatch-repair proficient (MSS) colorectal cancer.
- Trial name
- NCT03711058
- Testing
- Copanlisib, Nivolumab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioma, Rhabdomyosarcoma
Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
This study proposes to treat patients with the combination of erlotinib and temozolomide. Patients with relapsed, recurrent, refractory, or high risk malignancies whose tumors possess a non-synonymous mutation in EGFR, ERBB2, or…
- Conditions
- Glioma, Rhabdomyosarcoma, Osteosarcoma, Medulloblastoma
- Trial name
- NCT02689336
- Testing
- Erlotinib, Temozolomide
- Sponsor
- Washington University School of Medicine
Refractory and/or Relapsed Metastatic Solid Tumors
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk…
- Trial name
- NCT01804634
- Testing
- Cyclophosphamide, Fludarabine, low dose total body irradiation
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Solid Tumors, Adult
Study of ON 123300 in Patients With Advanced Cancer
This study will investigate the safety of the drug ON 123300 at increasing doses to determine the best dose to use in future clinical trials.
- Trial name
- NCT04739293
- Testing
- ON123300
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Traws Pharma, Inc.
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Pediatric Solid Tumor, Neuroblastoma
B7-H3.CD28Z.CART in Solid Tumors
The goal of this research study is to test if a new cell therapy (B7-H3.CD28Z.CART / B7-H3 CAR T cells) is safe and effective in treating children and young adults with solid cancers whose tumors have returned or stopped…
- Trial name
- NCT07358260
- Testing
- B7-H3.CD28Z.CART, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Robbie Majzner
Advanced Cancer, Solid Tumors
A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML
This research study is being done in people with advanced-stage solid tumor cancer. Advanced stage solid tumor cancer is a cancer that forms an abnormal mass of tissue that usually does not contain cysts or liquid areas.
- Conditions
- Advanced Cancer, Solid Tumors, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
- Trial name
- NCT03690154
- Testing
- FN-1501
- Where
- 3 sites in United States, Australia
- Volunteers
- 67 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Cancer, Pediatric Cancer
Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors
The primary purpose of this study is to determine the pediatric maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and to evaluate the safety and tolerability of zanzalintinib.
- Trial name
- NCT07773454
- Testing
- Zanzalintinib
- Volunteers
- 18 people
- Sponsor
- Exelixis
Hematologic Malignancies
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy
In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in patients with relapsed/refractory hematologic malignancies will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated…
- Trial name
- NCT05104775
- Testing
- GNC-035
- Where
- 7 sites in China
- Volunteers
- 33 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer
Evaluation of XYA02 in Patients With Advanced Solid Tumors
This study will evaluate the safety, tolerability, and efficacy of XYA02 in participants with advanced solid tumors.
- Conditions
- MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, GEJ Adenocarcinoma
- Trial name
- NCT07670312
- Testing
- XYA02
- Where
- 5 sites in Australia
- Volunteers
- 190 people
- Sponsor
- XYone Therapeutics, Inc
Solid Tumor, Lymphoma
Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.
- Trial name
- NCT03934814
- Testing
- TJ011133, Pembrolizumab, Rituximab
- Where
- 21 sites in United States, China
- Volunteers
- 98 people
- Sponsor
- I-Mab Biopharma US Limited
Advanced Solid Tumors, Lymphoma
A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
This is a first-time-in-human (FTIH), Phase 1 study to determine the safety, tolerability, maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and pharmacokinetics (PK) of AZD0466 in patients with solid tumors…
- Conditions
- Advanced Solid Tumors, Lymphoma, Multiple Myeloma, Hematologic Malignancies
- Trial name
- NCT04214093
- Testing
- AZD0466
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- AstraZeneca
Malignancy, Non-hodgkin Lymphoma
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with…
- Conditions
- Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer
- Trial name
- NCT03997968
- Testing
- CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine
- Where
- 16 sites in United States
- Volunteers
- 169 people
- Sponsor
- Cyteir Therapeutics, Inc.
Pediatric Brain Tumor, Pediatric Solid Tumor
Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
This is a pilot phase Ib study of the safety of dapagliflozin (in addition to standard of care treatment) for the treatment of pediatric patients with recurrent brain tumors and relapsed/refractory solid tumors.
- Trial name
- NCT05521984
- Testing
- Dapagliflozin, Carmustine, Topotecan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Neoplasms, Myelodysplastic Syndromes
Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors
Background: Researchers want to develop better ways to treat cancer. In this study, they will give people with cancer two drugs. These drugs have been used on their own to treat some blood cell cancers.
- Conditions
- Neoplasms, Myelodysplastic Syndromes, Lymphomas
- Trial name
- NCT02211755
- Testing
- Bortezomib plus Clofarabine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Studying Fentanyl in Patients With Cancer
RATIONALE: Studying blood samples from cancer patients undergoing pain treatment in the laboratory may help doctors learn more about how pain drugs work in the body.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00899951
- Testing
- fentanyl citrate, pharmacological study
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Solid Tumor, Adult
First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)
The Phase 1 part (Part A) is a dose escalation study of IV visugromab (CTL-002, a monoclonal antibody neutralizing GDF-15) as monotherapy and in combination with an approved checkpoint inhibitor (CPI) in patients with advanced…
- Trial name
- GDFATHER (NCT04725474)
- Testing
- visugromab (CTL-002), nivolumab
- Where
- 13 sites in Germany, Spain and 1 more
- Volunteers
- 199 people
- Sponsor
- CatalYm GmbH
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well palbociclib works in treating patients with Rb positive solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations (mutations) in cell cycle genes…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma
- Trial name
- NCT03526250
- Testing
- Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
- Where
- 117 sites in United States, Puerto Rico
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)